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The nucleotide sequence analysis of cloned cDNA for VIP precursor from rat cerebral cortex reveals that 
the precursor contains both rat VIP and PHI-27. The deduced primary structure of rat VIP is identical with 
human VIP. The amino acid sequence of rat PHI-27 differs by 4 amino acids from human PHM-27. When 
each VIP precursor is divided functionally into 6 domains, the amino acid sequence homology between rat 
and human precursors ranges from 69 to lOO*?& In contrast, any domain exhibits an essentially equal degree 
of nucleotide sequence homology. 
Rat VIP Rat PHI-27 VIP precursor VIP precursor m RNA Human PHM-27 Sequence homology 
1. INTRODUCTION 
Vasoactive intestinal polypeptide (VIP), a 28 
amino acid peptide originally isolated from por- 
cine duodenum [l], is present not only in 
gastrointestinal tissues but aIs0 neural tissues, 
possibly as a neurotransmitter [2,3]. VIP is struc- 
turally similar to members of the glucagon-secretin 
family, especially to porcine PHI-27 [4]. We found 
that the primary structure of the human VIP 
precursor, deduced from the DNA sequence com- 
plementary to the mRNA coding for human VIP, 
contains the sequences of both VIP and a novel 
PHI-27-like peptide, PHM-27 [.5,6]. We reported 
that the transcription rate of the VIP precursor 
mRNA in human neuroblastoma cells is regulated 
by cyclic AMP [7]. 
Abbreviations: VIP, vasoactive intestinal polypeptide; 
PHI-27, peptide having amino-termina1 histidine, 
carboxy-terminal isoleucine amide and 27 amino acid 
residues; PHM-27, peptide having amino-terminal 
histidine, carboxy-terminal methionine amide and 27 
amino acid residues; bp, base pairs 
* To whom correspondence should be addressed 
Here, we have determined the DNA sequence 
complementary to the mRNA coding for rat VIP 
precursor. The comparative analysis of nucleotide 
and amino acid sequence homologies of rat and 
human VIP precursors implies that selection 
pressures during evolution have eliminated base 
substitutions which might result in amino acid 
replacements. 
2. MATERIALS AND METHODS 
Guanidinium thiocyanate was purchased from 
Fluka; oligo(dT)-cellulose from Pharmacia P-L 
Biochemicals; restriction endonucleases from Nip- 
pon Gene (Toyama, Japan) and Takara Shuzo 
(Kyoto); avian myelomatosis virus reverse 
transcriptase from Seikagaku Kogyo (Tokyo); calf 
thymus terminal deox~ucleotidyl transferase 
from Takara Shuzo; E. co/i RNase H from Wako 
(Osaka); E. coli DNA ligase from Pharmacia P-L 
Biochemicals; E. coli DNA polymerase I from 
New England BioLabs; membrane filters for col- 
ony and blot hybridizations and DPT paper from 
Schleicher & Schuell; [*-32P]dCTP, dGTP, and 
TTP (spec. act. 3000 Ci/mmol) and an Ml3 clon- 
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ing kit from Amersham; an Ml3 sequencing kit 
from Takara Shuzo. 
2.2. Probe DNA for colony and blot 
hybridizations 
The 409-bp Sau3AI-EcoRI restriction fragment 
(nucleotide residues 148-556 in fig.l), which con- 
tains human VIP and PHM-27 cDNA sequences, 
was derived from human prepro-VIP/PHM-27 
cDNA clone pVIP-1 [5,6]. This fragment was 
labelled by nick-translation [B] with [a-32P]dCTP 
and used as a hybridization probe to screen for 
recombinant plasmids carrying rat VIP precursor 
cDNA sequences. 
2.3. Purification of RNA containing rat VIP 
precursor mRNA and cDNA cloning 
Total RNA was extracted from cerebral cortex 
of male Wistar rats as described previously [9]. 
About 400 pug of poly(A)+ RNA isolated by 
oligo(dT)-cellulose chromatography was applied to 
a linear 5-25% sucrose gradient, centrifuged at 
26 000 rpm at 20°C for 20 h in a Beckman SW27.1 
rotor, and fractionated [lo]. Glyoxalated RNA 
from each fraction was electrophoresed on a 1.5% 
agarose gel and transferred to DPT paper [ 111. The 
paper was hybridized with the nick-translated 
Sau3AI-EcoRI restriction fragment from human 
prepro-VIP/PHM-27 cDNA clone pVIP-1 and 
subjected to autoradiography [7]. RNA (about 9 
pg) was ethanol-precipitated from the hybridiza- 
tion-positive fraction. With this partially purified 
mRNA, cDNA cloning was performed according 
to the method of Okayama and Berg [12]. 
2.4. Transformation of E. coli strain DHl and 
screening 
Transformation of E. coli strain DHl was car- 
ried out according to the method of Shigesada 
[ 131. Ampicillin-resistant transformants were 
screened by colony hybridization [14] with the 
nick-translated Sau3AI-EcoRI restriction frag- 
ment from human prepro-VIP/PHM-27 cDNA 
clone pVIP-1. Sizes of cDNA inserts of candidate 
clones were estimated by Southern blot analysis 
[ill. 
2.5. DNA sequence analysis 
The largest cDNA insert was cleaved with 
various restriction endonucleases and the cleaved 
fragments were subcloned in Ml3 vectors mpl0 
and mpl 1 [ 151. The sequence of each restriction 
fragment was determined by the dideoxy chain- 
termination method [ 151. 
3. RESULTS 
The partially purified mRNA from rat cerebral 
cortex was 3-fold enriched over poly(A)+ RNA for 
rat VIP precursor mRNA by fractionation after 
passage through the sucrose density gradient. The 
content of rat VIP precursor mRNA was estimated 
at 0.005% by northern blot hybridization assays 
using the human VIP precursor cDNA (pVIP-l), 
and the rat VIP precursor mRNA was found to be 
about 1600 nucleotides long (unpublished). With 
the partially purified mRNA, cDNA cloning was 
performed according to the method of Okayama 
and Berg [12]. In the first screening, 11 
hybridization-positive clones were isolated from 
approx. 800000 transformants by colony 
- 
Fig. 1. Nucleotide and deduced amino acid sequences of rat VIP precursor mRNA cloned into pVIPrat-B, compared 
with human sequences. (A) The coding regions and (B) the 3 ’ nontranslated regions. Nucleotide residues are numbered 
in the 5 ’ to 3 ’ direction, beginning with the first residue of AUG triplet encoding the initiative methionine of the human 
VIP precursor mRNA. Amino acid residues are numbered beginning with the initiative methionine of the human VIP 
precursor [5,6]. The upper nucleotide sequence shows the rat VIP precursor mRNA and the deduced amino acid se- 
quence is given above this. The nucleotide and amino acid differences found in the human sequence are displayed 
beneath the rat sequence. Nucleotide sequences are aligned to give maximum homology with the introduction of 
minimal deletions. Deletions are indicated by colons on a one-to-one basis. The hyphens indicate sequences that have 
not been determined. A possible site for cleavage of a signal peptide is after amino acid residue 21 and possible 
glycosylation sites are at amino acid residues 68-70 and 133-135 [5]. The polyadenylation signals (AAUAAA) present 
downstream of the translational termination site are underlined. 
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hybridization with the nick-translated Sau3AI- 
EcoRI restriction fragment from human prepro- 
VIP/PHM-27 cDNA clone pVIP-1. We re- 
screened these 11 clones twice, and 3 independent 
clones varrying rat VIP precursor cDNA sequences 
were isolated. One of the clones, pVIPrat-B, which 
carried the largest cDNA insert (about 1500 bp 
long), was subjected to nucleotide sequence 
analysis by using Ml3 cloning and sequencing 
methods [15]. 
The nucleotide sequence of the mRNA coding 
for rat VIP precursor protein is shown in fig.1. 
The amino acid sequence (residues 125-152) 
deduced from the nucleotide residues 373-456 
coincides precisely to the amino acid sequence of 
human VIP [5]. The primary structure of rat VIP, 
deduced from the cDNA sequence of rat cerebral 
cortex in this study, is in agreement with that of rat 
VIP recently isolated from rat intestine [16]. 
The deduced amino acid sequence at residues 
81-107 has histidine as amino-terminus and 
isoleucine as carboxy-terminus and consists of 27 
amino acid residues. This amino acid sequence dif- 
fers by 1, 2, and 4 amino acid(s) from bovine 
PHI-27, porcine PHI-27, and human PHM-27, 
respectively [4,5,17]. Although rat PHI-27-like 
peptide has not been isolated, we estimate that the 
sequence of nucleotide residues 241-321 cor- 
responds to that of ‘rat PHI-27’. 
Thus, as shown in fig.lA, the rat VIP precursor 
contains both rat VIP and rat PHI-27, and has 
post-translational processing sites for generation 
of these two peptides. A pair of basic amino acid 
residues (Lys-Arg) precede the amino-terminus of 
rat VIP and only one basic amino acid (Arg) 
precedes the amino-terminus of rat PHI-27. A 
glycine and a pair of basic amino acids (Gly-Lys- 
Arg), a sequence which is known to be a carboxy- 
terminal amidation signal [18], lie adjacent to the 
carboxy-terminus of both rat VIP and rat PHI-27. 
These suggest that both rat VIP and rat PHI-27 are 
liberated from their precursor by proteolytic pro- 
cessing, and that the peptides are carboxy- 
terminally amidated. 
Two translation termination codons, UGA 
(nucleotide residues 51 l-516), are present at a site 
55 nucleotides downstream from the carboxy- 
terminus of rat VIP, as is observed in the 
nucleotide sequence of human VIP precursor 
mRNA [5,6], but the presumed initiation codon is 
58 
not found. As shown in fig.lA, our cDNA clone 
pVIPrat-B can encode 162 amino acids and human 
VIP precursor is 170 amino acids long. Thus, our 
cDNA clone pVIPrat-B may be missing 22 
nucleotides of the translated sequence in addition 
to the 5’-nontranslated sequence. 
As shown in fig. lB, the 3’-nontranslated regio 
of the rat VIP precursor mRNA is unusually long 
and has two polyadenylation sites, AAUAAA 
(nucleotide residues 633-638 and 1333-1338). The 
rat 3’-nontranslated region is 75% homologous to 
the human counterpart, when gaps are counted as 
one substitution regardless of their length. 
4. DISCUSSION 
In the preceding paper, we have shown the 
primary structure of human VIP precursor [5,6]. 
Here, nucleotide sequence analysis of the cloned 
cDNA pVIPrat-B has disclosed the primary struc- 
ture of rat VIP precursor. Comparison of rat and 
human VIP precursors has revealed that the posi- 
tioning of the processing sites for generation of 
VIP and PHI-27 in the rat VIP precursor is the 
same as that in the human precursor (fig.lA). As 
shown in fig.2, each VIP precursor protein is func- 
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Fig.2. Sequence homology of each functionally divided 
domain in rat and human VIP precursors and cor- 
responding mRNAs. The structure of the VIP precursor 
is presented schematically in the upper part of the figure. 
Numbering of the amino acid and nucleotide residues is 
as in fig. 1. Each VIP precursor is functionally divided 
into 6 domains by the post-translational processing sites, 
and percentage of homology is calculated in each do- 
main. Amino acid sequence homology is shown by shad- 
ed boxes and nucleotide sequence homology is solid 
lines. 
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tionally divided into 6 domains by post- 
translational processing sites (after amino acid 
residues 21, 80, 107, 124, and 152). The amino acid 
sequence for VIP is completely conserved in rat 
and human VIP precursors, while the degree of 
amino acid sequence homology of other domains 
varies from 69 to 90%. In contrast, at the 
nucleotide level, the degree of homology is 89% in 
the VIP domain and any domain exhibits an essen- 
tially equal degree of homology (7949%). 
Although these findings suggest that rat and 
human VIP precursor genes have evolved from a 
common ancestral gene, the comparative analysis 
of nucleotide and amino acid sequence homologies 
of each domain in rat and human VIP precursors 
implies that selection pressures have eliminated 
base substitutions which might result in amino acid 
replacements. In other words, the degree of amino 
acid sequence conservation of the peptide during 
evolution might strongly contribute to its essential 
biological functions. In fact, VIP is conserved in 
various mammalian species [I ,5,6,19,20] and ex- 
hibits important biological actions [21], but the 
physiological significance of PHI-27 and PHM-27 
is still nuclear. 
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